GHK-Cu, the copper peptide: what it is and what the studies show

GHK is a tripeptide, a short chain of three amino acids: glycine, histidine and lysine (glycyl-histidyl-lysine). It readily binds copper ions and forms a complex, GHK-Cu. That is why it is also called the "copper peptide".

GHK occurs naturally in human plasma. It was first described in the 1970s by Loren Pickart, and its sequence was identified in 1977 (Schlesinger, Pickart and Thaler, Experientia 1977, PMID 858356).

The same substance circulates under several names, and that is where the confusion starts. "Copper peptide" and "copper tripeptide" are the everyday terms. Cosmetic ingredient lists write copper tripeptide-1, which is the labelling name. The literature writes GHK-Cu or glycyl-histidyl-lysine-Cu.

The trade names found on serums describe the composition of one specific product, not a different peptide.

GHK is also produced inside the body. A 2026 systematic review describes it as a matricryptin: a fragment released from larger connective-tissue proteins, specifically from the collagen Iα2 chain and from the SPARC protein (Najafi et al., Arch Intern Med Res 2026, PMID 42787770).

The same review describes the copper in the complex as an essential cofactor for the lysyl oxidase family, the enzymes that cross-link collagen and elastin fibres. That is a description of mechanism, not a measurement of outcome.

GHK-Cu is sold as an ingredient in cosmetic products, usually serums and creams labelled "copper peptide". These are finished cosmetic formulations with a specific composition.

Research GHK-Cu is the substance as a powder, for laboratory use. The few human studies that have been published concern cosmetic formulations applied to the skin. They do not concern the research material, and their findings do not carry over to it.

Most data on GHK-Cu come from laboratory studies in cells and from experimental models in animals:

• Fibroblast cultures (Maquart et al., FEBS Lett 1988, PMID 3169264): in connective-tissue cells an increase in collagen synthesis was measured.
• Experimental model in rats (Maquart et al., J Clin Invest 1993, PMID 8227353): increased accumulation of collagen and glycosaminoglycans was measured in the model tissue.
• Experimental model in rabbits (Cangul et al., Vet Dermatol 2006, PMID 17083573): a tripeptide-copper complex was applied to the skin in an open-wound model in 18 rabbits, compared with zinc oxide and with no application. Wound area and histology were measured.
• Gene expression (Pickart et al., Biomed Res Int 2014, PMID 25302294): a computational analysis of public gene-expression databases, not an experiment in humans; authors from Skin Biology.

In humans, a PubMed search on 26/10/2026 (terms: GHK-Cu, copper peptide or copper tripeptide, combined with skin, wrinkle or collagen, with a clinical-trial filter) found one randomised trial in humans. In it, 13 participants who completed the programme used skin-care products with or without GHK-Cu after ablative CO2 laser resurfacing of an area of the face (Miller et al., Arch Facial Plast Surg 2006, PMID 16847171). Objective measurements showed no difference between groups for redness, wrinkles or overall skin quality, and both groups improved. In the questionnaire, the improvement in overall skin quality was rated higher by the GHK-Cu group (P = 0.04).

The most recent systematic review of GHK-Cu was published in August 2026 (Najafi et al., Arch Intern Med Res 2026, PMID 42787770). The authors searched PubMed, ScienceDirect and the Cochrane CENTRAL registry for publications from 2005 to 2026. Of 1,247 records, 64 were retained after screening.

They describe the four decades of preclinical work as deep and mechanistically coherent. For the human data they write that the clinical literature remains thin and fragmented, with randomised trials that are small and mostly run on facial cosmetic creams.

The review closes with design proposals for trials that are called for and do not yet exist.

GHK-Cu is markedly hydrophilic. That limits its passage into the deeper layers of the skin, which is why analytical research tests carriers such as liposomes and measures the stability of the complex inside complex cosmetic bases (Ogórek et al., J Chromatogr A 2026, PMID 42887096).

This changes how the studies are read. A 2026 review of peptides in aesthetic dermatology concludes that the evidence is interpreted per product and is not interchangeable across peptide classes or different compositions (Yi et al., Life 2026, PMID 42942246). Two products with the same ingredient on the label do not have the same evidence behind them.

The studies on GHK-Cu are small and most were done in cells or animals. The 2014 review cited here (PMID 25302294) has authors from the research and development department of Skin Biology, a company that sells skin-care products with GHK-Cu. Research in humans is at an early stage, with few participants, short follow-up and different product compositions.

The 2026 review of aesthetic dermatology adds a second gap, one about the material rather than the outcome: the literature does not establish universal purity thresholds or shelf lives for formulations (Yi et al., Life 2026, PMID 42942246). That is why batch documentation is judged batch by batch.

The two names sound alike but describe different things. GHK-Cu is one specific tripeptide bound to copper. "Collagen peptides" are a mixture of small collagen fragments, made by breaking down animal collagen and sold mainly as food supplements. They contain no copper and are not the same molecule. More on the categories of peptides in the guide "What are peptides".

A certificate of analysis records the purity of the substance measured by HPLC, its identity, the laboratory that ran the analysis and the batch number it refers to. Published certificates are in the COA library.

• Schlesinger DH, Pickart L, Thaler MM. Experientia. 1977. PMID 858356 · DOI 10.1007/BF02002806
• Maquart FX et al. FEBS Lett. 1988. PMID 3169264 · DOI 10.1016/0014-5793(88)80509-x
• Maquart FX et al. J Clin Invest. 1993. PMID 8227353 · DOI 10.1172/JCI116842
• Cangul IT et al. Vet Dermatol. 2006. PMID 17083573 · DOI 10.1111/j.1365-3164.2006.00551.x
• Miller TR et al. Arch Facial Plast Surg. 2006. PMID 16847171 · DOI 10.1001/archfaci.8.4.252
• Pickart L et al. Biomed Res Int. 2014. PMID 25302294 · DOI 10.1155/2014/151479
• Najafi N et al. Arch Intern Med Res. 2026. PMID 42787770 · DOI 10.26502/aimr.0255
• Yi KH et al. Life (Basel). 2026. PMID 42942246 · DOI 10.3390/life16101660
• Ogórek K et al. J Chromatogr A. 2026. PMID 42887096 · DOI 10.1016/j.chroma.2026.467540

An informational text summarising published research. It is not medical or cosmetic advice or usage guidance.